We are live on ! Find out more
SLDB icon

Solid Biosciences
SLDB

64 hedge funds and large institutions have $616M invested in Solid Biosciences in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more capital invested

Capital invested by funds: $119M → $616M (+$498M)

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

10% more funds holding

Funds holding: 58 → 64 (+6)

0.15% more ownership

Funds ownership: 3.11% → 3.26% (+0.15%)

Holders
64
Holders Change
+6
Holders Change %
+10.34%
% of All Funds
1.47%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
20
Increased
22
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$41.6M
2
PHS
PFM Health Sciences
California
+$9.63M
3
AC
Armistice Capital
New York
+$3.69M
4
DM
Deerfield Management
New York
+$3.68M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.47M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.15M
2
Millennium Management
Millennium Management
New York
-$5.03M
3
JP Morgan Chase
JP Morgan Chase
New York
-$2.98M
4
GTC
Ghost Tree Capital
New York
-$2.89M
5
ACA
Avoro Capital Advisors
New York
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
1
JP Morgan Chase
New York
$114M -$2.98M -9,687 -4%
BC
2
Boxer Capital
California
$99.1M +$41.6M +135,333 +271%
RCM
3
RA Capital Management
Massachusetts
$95.8M – – –
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$70.9M – – –
CAM
5
Cormorant Asset Management
Massachusetts
$24.4M -$308 -1 -0%
RI
6
RTW Investments
New York
$22.8M – – –
BlackRock
7
BlackRock
New York
$21.2M -$891K -2,895 -7%
BBA
8
Baker Bros. Advisors
New York
$20.9M – – –
PHS
9
PFM Health Sciences
California
$16.7M +$9.63M +31,291 New
EAM
10
Eventide Asset Management
Massachusetts
$14.3M – – –
Wellington Management Group
11
Wellington Management Group
Massachusetts
$14.2M +$1.82M +5,929 +29%
Vanguard Group
12
Vanguard Group
Pennsylvania
$13.2M +$212K +689 +3%
FCMI
13
Foresite Capital Management III
California
$12M – – –
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
$8.91M -$6.15M -20,000 -55%
AG
15
Artal Group
Luxembourg
$8.91M +$2.05M +6,667 +67%
AC
16
Armistice Capital
New York
$6.41M +$3.69M +12,000 New
DM
17
Deerfield Management
New York
$6.39M +$3.68M +11,959 New
State Street
18
State Street
Massachusetts
$5.15M +$1.02M +3,309 +52%
Balyasny Asset Management
19
Balyasny Asset Management
Illinois
$4.29M +$2.47M +8,023 New
Northern Trust
20
Northern Trust
Illinois
$3.96M +$399K +1,296 +21%
RSCM
21
Rock Springs Capital Management
Maryland
$3.38M -$615K -2,000 -24%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.92M +$452K +1,469 +37%
WM
23
WS Management
Florida
$2.84M +$1.63M +5,313 New
HIM
24
Hillhouse Investment Management
Cayman Islands
$2.49M – – –
SIM
25
Spark Investment Management
New York
$2.28M +$1.31M +4,266 New
1
2 3 4

SLDB Hedge Fund Activity: Q2 2018 in Review

64 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2018, worth a combined $616M — up 420% from $119M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new SLDB positions and 13 closed out — a net gain of 7 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was Boxer Capital, adding an estimated $41.6M. The largest seller was Adage Capital Partners, cutting an estimated $6.15M.

  • 64 institutional investors held Solid Biosciences (SLDB) as of Q2 2018, up from 58 in Q1 2018.
  • Funds reported $616M of Solid Biosciences stock for Q2 2018, up 420% quarter-over-quarter.
  • 20 funds opened new Solid Biosciences positions in Q2 2018 and 13 closed out, a net change of +7 holders.
  • The largest Solid Biosciences buyer in Q2 2018 was Boxer Capital, an estimated $41.6M added.
  • The largest Solid Biosciences seller in Q2 2018 was Adage Capital Partners, an estimated $6.15M sold.

Based on aggregated 13F filings for Q2 2018.